Platelet Patents (Class 424/93.72)
-
Publication number: 20120082652Abstract: A method provides for procuring platelet rich plasma (PRP) from a sample of whole blood in a vial. The method includes the steps of: separating the whole blood into layers through centrifugation with an upper layer containing platelet poor plasma (PPP) and a PRP layer below the upper layer containing PRP; adjusting an end point of a first range of motion of an extractor relative to a position of the PRP layer; moving the extractor through the first range of motion through the vial, PPP passing out from the upper layer through the extractor; and after the extractor reaches the end point of the first range of motion, extracting the PRP through the extractor and collecting the PRP.Type: ApplicationFiled: September 30, 2010Publication date: April 5, 2012Applicant: DePuy Miltek, Inc.Inventors: Mehmet Ziya Sengun, William Parrish, Brooks J. Story, Kristian DiMatteo, Gregory R. Whittaker, Douglas Allen Fifolt
-
Publication number: 20120082715Abstract: A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.Type: ApplicationFiled: September 2, 2011Publication date: April 5, 2012Inventor: David Needham
-
Publication number: 20120076837Abstract: In one aspect, the invention relates to providing enhanced application tissue graft materials in regenerative medicine through improved cellular interactions. Biocompatible implant materials, methods for preparing biocompatible implant materials, methods for using same, and methods for treating tissue injury are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: December 2, 2011Publication date: March 29, 2012Inventors: V. Prasad Shastri, Henrique Franca Diniz Oliveira
-
Publication number: 20120070420Abstract: Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue.Type: ApplicationFiled: November 22, 2011Publication date: March 22, 2012Inventor: Allan Mishra
-
Patent number: 8137663Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: GrantFiled: March 26, 2009Date of Patent: March 20, 2012Assignee: Wellstat Biologics CorporationInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Patent number: 8124130Abstract: Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations of the present invention preferably include platelet-rich plasma with a pharmaceutical agent. The pharmaceutical agent may be a glucocorticoid hormone or other organic pharmaceutical agent. Particularly preferred pharmaceutical agents include dexamethasone, melatonin, purmorphamine, 17?-estradiol, vitamin K2 (menaquinone-4, MK4), bisphosphonates, derivatives thereof, and combinations thereof. The formulations of the present invention may be directly administered to a surgical or injury site where improved bone growth is desired. The formulations may also be applied to or otherwise incorporated into scaffolding structural components commonly employed in the medical field to promote bone structure and growth. The pharmaceutical agent may be employed in an immediate release form or a sustained release form.Type: GrantFiled: May 30, 2008Date of Patent: February 28, 2012Inventor: James Louis Rutkowski
-
Publication number: 20120045424Abstract: An assembly comprising: (a) a test tube for receiving a blood sample or a platelet-comprising fraction thereof and for obtaining therein, by a procedure that includes centrifugation, a platelet rich plasma (PRP) fraction; (b) an elongated filter device having a first and second end and a lumen extending there between, and having a filter fitted at the first end, the filter having a effective pore size such to permit passage of platelets and not permit passage of white blood cells (WBC) larger than a defined size into the lumen, the second end having an opening; the first end of the elongated filter device being adapted for tight fitting into said test tube such that when forced into the test tube to exert pressure on the PRP fraction, the PRP fraction with the platelets filters into said lumen and white blood cells of a size large than said defined size remain in the test tube to thereby obtain a WBC-selective PRP within said lumen.Type: ApplicationFiled: April 19, 2010Publication date: February 23, 2012Inventor: Aaron Esteron
-
Publication number: 20120027740Abstract: A method regenerates specific tissue, preferably mesenchymal tissues like bone, fat, tendon, muscle, cartilage and marrow stroma and hematological tissue (RBC, WBC, platelets, lymphocytes, hematological stem cells (HSC), endothelial progenitor cells (EPC) etc.). A method for reconstructing, regenerating, rejuvenating or reinforcing a damaged or diseased tissue in a mammal subject, and preferably a human patient, uses a (regenerated) tissue obtained by this method.Type: ApplicationFiled: February 5, 2010Publication date: February 2, 2012Inventor: Pierre Philippart
-
Publication number: 20120014933Abstract: The present invention relates to a method for producing platelets from mature megakaryocytes. More particularly, the invention relates to an ex vivo method for producing platelets, from mature megakaryocytes, said method comprising a step of subjecting a suspension of mature megakaryocytes to a flow having a minimal shear rate of 600 s?1 on a solid phase coated with Von Willebrand factor.Type: ApplicationFiled: December 4, 2009Publication date: January 19, 2012Applicants: INSERM (Institut National de la Sante et al Recherche Medicate ), Universite de Versailles Saint-Quentin-en-Yvelines, Assistance Publique Hopitaux de Paris, Universite Paris DescartesInventors: Dominique Baruch, Elisabeth Cramer-Borde, Claire Dunois
-
Patent number: 8097403Abstract: The present invention provides freeze-dried platelets and compositions comprising freeze-dried platelets for use as a diagnostic and calibration reagent for blood coagulation function. The invention also provides methods of diagnosing or monitoring blood coagulation function, including diagnosing or monitoring blood coagulation diseases and disorders. Kits for performing the methods of the invention are also included.Type: GrantFiled: December 14, 2007Date of Patent: January 17, 2012Assignee: Cellphire, Inc.Inventors: David Ho, Heather Jones
-
Patent number: 8088371Abstract: Methods are described for using compositions containing platelet-rich plasma for the treatment of peripheral vascular disease. A platelet-rich plasma composition is introduced into the muscle or soft tissue in the area of hypovascularity to treat the peripheral vascular disease.Type: GrantFiled: June 17, 2008Date of Patent: January 3, 2012Inventor: Allan Mishra
-
Publication number: 20110318319Abstract: Methods for forming activated platelet gels using nsPEF's and applying the activated gels to wounds, such as heart tissue after myocardial infarction. The platelets are activated by applying at least one nsPEF with a duration between about 10 picoseconds to 1 microsecond and electrical field strengths between about 10 kV/cm and 350 kV/cm.Type: ApplicationFiled: November 13, 2009Publication date: December 29, 2011Inventors: Barbara Y. Hargrave, Peter F. Blackmore, Stephen J. Beebe, Karl H. Schoenbach
-
Publication number: 20110318299Abstract: The present invention discloses a composition for accelerating nerve repair. The composition comprises platelet-rich fibrin, a growth factor and a cytokine. The composition may further comprise a tissue with a stem cell or a neural tube to be a scaffold for promoting nerve generation. The platelet-rich fibrin is obtained from the blood of the mammal to be operated on with a nerve repair.Type: ApplicationFiled: August 31, 2010Publication date: December 29, 2011Applicant: TAIPEI MEDICAL UNIVERSITYInventor: Wing-Pong Chan
-
Patent number: 8084236Abstract: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.Type: GrantFiled: June 4, 2007Date of Patent: December 27, 2011Inventor: Robert Sackstein
-
Patent number: 8052969Abstract: A method of providing autologous conditioned plasma (ACP) for treatment of connective tissue injuries. The method comprises the steps of: (i) providing an apparatus comprising a centrifuge and a double syringe, the double syringe including an inner syringe body and an outer syringe body; (ii) drawing autologous blood into the outer syringe body; (iii) subjecting the autologous blood to at least one centrifugation step to obtain an autologous conditioned plasma (ACP); (iv) removing, with the inner syringe body, at least a portion of autologous conditioned plasma (ACP) from the outer syringe body; and (v) inject ACP for treatment of various cartilage or tendon damage or diseases.Type: GrantFiled: December 21, 2007Date of Patent: November 8, 2011Assignee: Arthrex, Inc.Inventors: Michael Buhr, Werner Siekmann, Stèphane Naudin
-
Publication number: 20110256205Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.Type: ApplicationFiled: October 6, 2010Publication date: October 20, 2011Applicant: The Invention Science Fund I, LLCInventors: Ed Harlow, Edward K.Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, JR.
-
Patent number: 8034014Abstract: Methods for promoting angiogenesis comprising administering platelet-rich plasma to a site and stimulating the site with an electromagnetic field. Platelets include platelet-rich plasma and compositions can further include stem cells such as adipose stromal cells and cells derived from bone marrow aspirate. Methods also comprise isolating platelets from a patient's blood, forming a composition including the platelets, delivering the composition to a site in need of treatment, and electrically stimulating the site.Type: GrantFiled: March 6, 2007Date of Patent: October 11, 2011Assignee: Biomet Biologics, LLCInventors: Joel C. Higgins, Bruce Simon, Jennifer E. Woodell-May
-
Publication number: 20110245804Abstract: Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof.Type: ApplicationFiled: December 4, 2009Publication date: October 6, 2011Applicant: REGENERATIVE SCIENCES, LLCInventor: Christopher J. Centeno
-
Publication number: 20110189151Abstract: The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.Type: ApplicationFiled: December 27, 2010Publication date: August 4, 2011Inventors: Thomas P. STOSSEL, John H. Hartwig, Karin M. Hoffmeister, Henrik Clausen
-
Publication number: 20110159053Abstract: The present invention is directed to methods and compositions regarding the preparation of an cell concentrate, such as, for example, an osteogenic cell concentrate, from a physiological solution, such as bone marrow aspirate, blood, or a mixture thereof. In specific embodiments, the invention provides methods and compositions utilizing two physiological solution-processing techniques, particularly in a point of care environment, wherein centrifugation is not employed.Type: ApplicationFiled: March 2, 2011Publication date: June 30, 2011Inventors: Samuel O. Sowemimo-Coker, Marcus L. Scott, Marc Long, Ed Margerrison, Michael B. Cooper
-
Publication number: 20110142793Abstract: The present invention provides a composition for treating an articular cartilage defect and a manufacturing method thereof. The composition comprises a cartilage fragment and platelet-rich fibrin (PRF), and is transplanted to a surface of the defective cartilage of a mammal in order to treat the articular cartilage defect. Wherein the cartilage fragment is acquired from the cartilage of the same mammal, and the PRF is acquired from the blood of the same mammal.Type: ApplicationFiled: June 28, 2010Publication date: June 16, 2011Applicant: TAIPEI MEDICAL UNIVERSITYInventor: WING-PONG CHAN
-
Publication number: 20110123503Abstract: The present invention relates to platelet fractions which can be obtained from placental blood, with high concentrations of platelet factors as well as gels and lysates deriving therefrom. The invention further relates to methods for preparing said platelet fractions from placental blood, and to the uses thereof as such or as platelet gels or as lysates.Type: ApplicationFiled: July 14, 2009Publication date: May 26, 2011Applicant: Fondazione IRCCS "Ca'Granda - Ospedale Maggiore Policlinico"Inventors: Paolo Rebulla, Lorenza Lazzari, Valentina Parazzi, Noemi Greppi
-
Publication number: 20110117171Abstract: Compositions and methods are provided for promoting bone growth. An implantable bone graft material is provided comprising a resorbable ceramic and a resorbable polymer, wherein the polymer comprises a covalently attached stem cell binding peptide. The implantable bone graft materials are useful for promoting bone growth in a subject.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Applicant: AFFINERGY, INC.Inventors: Mora Carolynne Melican, Isaac Gilliam Sanford, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Martyn Kerry Darby
-
Publication number: 20110117167Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Applicant: AFFINERGY, INC.Inventors: Isaac Gilliam Sanford, Michelle Steffen Jansen, Paul Theodore Hamilton, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Yuchen Chen, Martyn Kerry Darby, Hanne Gron, Ganesan Sathya
-
Patent number: 7939063Abstract: Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is a secretory cell. The cell is a megakaryotic progenitor cell, or a cell further differentiated therefrom, such as a platelet. The cell is a granulocyte/macrophage progenitor cell or a cell further differentiated therefrom, such as a mast cell or neutrophils. Such host cells containing the molecule or the molecule itself are employed in methods for treating or preventing infection, inflammation or vascular injuries or any disorders involving or mediated by cells of the hematopoietic lineage.Type: GrantFiled: October 16, 2006Date of Patent: May 10, 2011Assignees: The Trustees of the University of Pennsylvania, The Children's Hospital of PhiladelphiaInventors: Douglas B. Cines, Mortimer Poncz
-
Publication number: 20110097381Abstract: A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or more viable cells that can migrate from the tissue and populate the tissue carrier matrix. Also provided is a method for injectably delivering the tissue implant.Type: ApplicationFiled: December 29, 2010Publication date: April 28, 2011Applicant: DEPUY MITEK, INC.Inventors: Francois Binette, Joseph J. Hammer, Krish Mukhopadhyay, Joel Rosenblatt
-
Patent number: 7923203Abstract: The present invention is directed to methods and compositions regarding the preparation of an cell concentrate, such as, for example, an osteogenic cell concentrate, from a physiological solution, such as bone marrow aspirate, blood, or a mixture thereof. In specific embodiments, the invention provides methods and compositions utilizing two physiological solution-processing techniques, particularly in a point of care environment, wherein centrifugation is not employed.Type: GrantFiled: October 5, 2007Date of Patent: April 12, 2011Assignees: Pall Corporation, Smith & Nephew, Inc.Inventors: Samuel O. Sowemimo-Coker, Marcus Lee Scott, Marc Long, Ed Margerrison, Michael B. Cooper
-
Patent number: 7910135Abstract: The present invention relates to a method of forming shape-retentive and shape-conforming aggregate wound dressings and biomaterials composed of gel nanoparticles and wound or bodily fluid in which the aggregates are held together by non-covalent bond physical forces such as, without limitation, hydrophobic-hydrophilic interactions and hydrogen bonds. The method comprises introducing a dry powder of gel nanoparticles to a wound site in which the nanoparticles absorb some of the blood or wound exudate and coalesce in situ into the claimed shape-retentive aggregate dressing. The method also comprises introducing the dry nanoparticle powder in or on a wet bodily tissue in vivo to form the claimed shape-retentive biomaterial. In addition, the method also comprises incorporating biomedical agents to produce medicated aggregate dressings or biomaterials for a variety of medical applications. This invention also relates to uses of the method of formation of the shape-retentive aggregates of gel nanoparticles.Type: GrantFiled: October 13, 2006Date of Patent: March 22, 2011Assignee: ULURU Inc.Inventors: John St. John, Daniel G. Moro
-
Patent number: 7901674Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the sane. The blood cells may be red blood cells or blood platelets.Type: GrantFiled: May 21, 2007Date of Patent: March 8, 2011Assignee: The University of North Carolina at Chapel HillInventors: Timothy C. Nichols, Thomas Fischer, Marjorie S. Read
-
Publication number: 20110052533Abstract: Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.Type: ApplicationFiled: March 13, 2009Publication date: March 3, 2011Applicant: REGENERATIVE SCIENCES, LLCInventor: Christopher J. Centeno
-
Publication number: 20110045051Abstract: The present invention describes an extracellular matrix comprising human platelet derived growth factors, that permits the maximising of therapeutic efficacy, combining the benefits of both components, to result in a more efficient and rapid integration of the matrix up to the structurally organised reconstruction of the neoformed tissue “in vivo”Type: ApplicationFiled: April 3, 2009Publication date: February 24, 2011Inventor: Carlo Mirabella
-
Patent number: 7892535Abstract: This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood. The invention is also directed towards a process for preventing rejection of a donor organ by a recipient comprising the steps of transfusing the recipient of the donor organ with treated platelets; and transplanting the donor organ into the recipient.Type: GrantFiled: December 3, 2009Date of Patent: February 22, 2011Assignee: CaridianBCT Biotechnologies, LLCInventors: Raymond P. Goodrich, Junzhi Li
-
Patent number: 7892726Abstract: The invention provides a method for the sterilization of a biological preparation comprising desired viable biological entities. The method comprises irradiating a dried (e.g. freeze-dried) biological preparation with ionizing or UV radiation at an intensity and for a duration sufficient to reduce the amount or activity of living-matter contaminants in the biological preparation, the intensity and duration selected such that at least part of the desired biological entities in the sample remains viable. The method of the invention is particularly suitable for the reduction of the amount or activity of contaminants such as bacteria or viruses from biological preparations comprising red blood cells or platelets.Type: GrantFiled: June 7, 2005Date of Patent: February 22, 2011Assignee: Core Dynamics LimitedInventors: Yehudit Natan, Tamir Kanias
-
Patent number: 7875454Abstract: A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations thereof, exposing the target tissue to the ionizing radiation. The delivery vehicle includes the active agent and delivers the agent to the target tissue. Representative delivery vehicles include platelets; leukocytes; proteins or peptides which bind activated platelets; antibodies which bind activated platelets; microspheres coated with proteins or peptides which bind activated platelets; liposomes conjugated to proteins or peptides, platelets, or leukocytes which bind activated platelets, or antibodies which bind activated platelets; and combinations thereof.Type: GrantFiled: April 28, 2006Date of Patent: January 25, 2011Assignee: Vanderbilt UniversityInventor: Dennis E. Hallahan
-
Publication number: 20110002880Abstract: The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable ?-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission.Type: ApplicationFiled: December 4, 2008Publication date: January 6, 2011Applicant: 3-D MATRIX, LTD.Inventors: Kentaro Takamura, Jiro Takei
-
Publication number: 20100297208Abstract: The present invention relates to scaffolds which can be used as medical devices for guided tissue regeneration and repair, in particular the invention is directed to a scaffold comprising fibres having a mean fibre diameter of between from about 1.2 to 4.0 microns, wherein the fibres comprise a glycolide. The invention further relates to the use of the scaffolds for the selective capture of cell populations for a cell source material.Type: ApplicationFiled: May 10, 2007Publication date: November 25, 2010Inventors: Nicholas Fry, Anthony Dagger, David Morsley, Helene Lecomte, Roy Trayhearn, Mark Howard, Sarah Freestone, Brian Thomson, Mark Smith, Rebecca Crallan
-
Publication number: 20100280493Abstract: Methods and systems are disclosed for treating cardiac tissue by delivering a platelet composition which induces neovascularization in the cardiac tissue followed by a cell preparation which induces regeneration in the re-vascularized tissue. The platelet composition can additionally contain structural materials and/or bioactive agents.Type: ApplicationFiled: January 3, 2007Publication date: November 4, 2010Inventor: Asha Nayak
-
Publication number: 20100266562Abstract: The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action.Type: ApplicationFiled: June 30, 2010Publication date: October 21, 2010Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, INNOVATIVE BIOTHERAPIES, INC.Inventors: H. David Humes, Deborah Buffington
-
Patent number: 7811558Abstract: The present invention provides compositions comprising freeze-dried platelets, microparticles, or both for use as a hemostat, such as for treating bleeding or injuries associated with bleeding. It also provides methods of treating injuries or wounds, and methods of causing blood to clot. Likewise, it provides methods of promoting healing of wounds or of healing wounds.Type: GrantFiled: August 12, 2005Date of Patent: October 12, 2010Assignee: Cellphire, Inc.Inventors: David Ho, Cindy S. Orser, Alan S. Rudolph
-
Publication number: 20100255059Abstract: A micro-scale artificial gland is disclosed in the form of an independent unit for promoting biological activity. The artificial gland includes cells formed in a membrane enclosing a reservoir. The reservoir is a bio-reactor capable of containing a product of activity of the cells. The reservoir comprises a gas, a liquid, and a gel and preferably also contains nanoparticles, a buffer, a surfactant, and, a gel precursor. The reservoir may also contain cells. Nanoparticles may also surround the artificial gland to form a protective coating. A variety of methods are disclosed for making the artificial gland by directed assembly of cells into the artificial micro-gland by gel, liquid or bubble templating. All involve coating the surface of gel, droplet or bubble with the living cells and the stabilizing the cells on the surface of gels, droplets or bubbles.Type: ApplicationFiled: March 17, 2010Publication date: October 7, 2010Applicant: YNANO, LLCInventors: Manuel Marquez, Samantha M. Marquez, Antonio Garcia
-
Publication number: 20100226902Abstract: An improved method for treating wounds with an enriched platelet composition is provided in which a small amount of a patient's blood is used to prepare, at point-of-care, a platelet-rich plasma (PRP) from which a gel is produced. The method involves the use of improved materials to improve the ease and speed at which wounds may be treated at the point-of-care.Type: ApplicationFiled: June 30, 2006Publication date: September 9, 2010Applicant: CYTOMEDIX, INC.Inventor: Carelyn P. Fylling
-
Publication number: 20100226903Abstract: A method of delivering therapy to a target site. The method includes (a) obtaining a base image of the target site, (b) injecting a dose of a mix of a therapeutic agent and a contrast agent into a first injection location at the target site via a needle passing through a catheter, (c) collecting sequential fluoroscopic images of a contrast agent dispersion cloud at the first injection location, (d) determining a contrast agent dispersion area from the sequential fluoroscopic images, (e) determining a therapeutic agent dispersion area from the contrast agent dispersion area, (f) marking the therapeutic agent dispersion area on the base image of the target site, and (g) repeating (b) through (f) until the target site is substantially covered with overlapping therapeutic agent dispersion areas corresponding to a plurality of injections at a plurality of injection locations at the target site.Type: ApplicationFiled: March 9, 2009Publication date: September 9, 2010Applicant: Medtronic, Inc.Inventors: Mary M. Morris, Kenneth Gardeski, Laurent Verard, Kevin Thomas Wu, Michael R. Neidert
-
Publication number: 20100221233Abstract: The present invention provides compositions and methods for enhancing the neuroprotective effect of umbilical cord blood cells. More particularly, the present invention provides methods of treating neurodegenerative disorders by administering umbilical cord blood cells and a substance capable of permeabilizing the blood brain barrier. In one embodiment, the blood brain barrier permeabilizer is mannitol. In another embodiment, the blood brain barrier permeabilizer is Cereport.Type: ApplicationFiled: March 8, 2010Publication date: September 2, 2010Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Cesario V. Borlongan, Paul R. Sanberg
-
Publication number: 20100196337Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.Type: ApplicationFiled: April 23, 2008Publication date: August 5, 2010Inventors: John M. Perry, Linheng Li, Justin C. Grindley
-
Publication number: 20100178314Abstract: Methods for producing porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions made by the processes of the present invention are useful clinically, per se or as cell-bearing implants.Type: ApplicationFiled: March 25, 2010Publication date: July 15, 2010Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Publication number: 20100150892Abstract: Methods of repairing and regenerating hard or soft tissue and reducing inflammation, anti-angiogenesis and anti-osteogenesis in a mammal and related methods of removing PF4 from platelets containing blood preparations. In one embodiment, the method comprises administering to a mammal platelets containing blood preparation where the PF4 has been reduced from the platelet containing blood preparation to repair and regenerate hard and soft tissue in the mammal.Type: ApplicationFiled: December 16, 2009Publication date: June 17, 2010Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventor: Bo Han
-
Publication number: 20100143317Abstract: The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.Type: ApplicationFiled: December 2, 2009Publication date: June 10, 2010Inventors: Andrew Pecora, Robert Preti
-
Patent number: 7718167Abstract: A method for treating an open wound, such as a surgical wound, may include preparing a first composition including a platelet poor plasma (PPP), and preparing a second composition including a platelet rich plasma (PRP). A layer of the first composition may be applied within the open wound, and a layer of the second composition may be applied within the open wound over the layer of the first composition.Type: GrantFiled: September 13, 2005Date of Patent: May 18, 2010Inventor: Richard A. Hynes
-
Publication number: 20100112014Abstract: Disclosed are novel agarose, methylcellulose, and dextran hydrogels. Further disclosed are methods of making and using the hydrogels.Type: ApplicationFiled: April 9, 2009Publication date: May 6, 2010Inventors: Ryan J. Gilbert, Benton C. Martin, Matthew M. Pap, Eric J. Minner
-
Publication number: 20100092444Abstract: Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets and white blood cells than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.Type: ApplicationFiled: October 8, 2009Publication date: April 15, 2010Applicant: BioParadox, LLCInventor: Allan Kumar Mishra